A totally redesigned host/vector system with improved initiator protein, protein, encoded by the pir gene limiting properties in terms of safety has been developed. The its host range to bacterial strains that produce this transpCOR plasmids are narrow-host range plasmid vectors for acting protein; (2) the plasmid's selectable marker is not an nonviral gene therapy. These plasmids contain a conantibiotic resistance gene but a gene encoding a bacterial ditional origin of replication and must be propagated in a suppressor tRNA. Optimized E. coli hosts supporting specifically engineered E. coli host strain, greatly reducing pCOR replication and selection were constructed. High the potential for propagation in the environment or in yields of supercoiled pCOR monomers were obtained (100 treated patients. The pCOR backbone has several features mg/l) through fed-batch fermentation. pCOR vectors carrythat increase safety in terms of dissemination and selecing the luciferase reporter gene gave high levels of lucifertion: (1) the origin of replication requires a plasmid-specific ase activity when injected into murine skeletal muscle.
Two different types of DNA vehicles, based on recombinant viruses and bacterial DNA plasmids, are used in gene therapy. Although virus-based vectors are widely used and very efficient vectors, the potential risks of viral gene delivery have to be seriously considered. E. coli plasmid-based vectors are non-infectious and versatile vehicles for gene therapy. The manufacture of therapeutic plasmid DNA that carries potent human genes becomes a reality. Thus, new approaches that take into account safety and environmental consideration must be developed.
Vector design is a major contributor to the safety of production and therapy. Efforts to improve the plasmid backbone have focused on the improvement of transgene expression 1 or plasmid copy number 2 but no rational design in terms of dissemination or size, has been reported. The ColE1-derived bacterial plasmids are currently used in gene therapy experiments and clinical trials. As far as the safety and containment of such genetic material are concerned, two elements are deleterious: the ColE1 origin of replication and the antibiotic resistance marker. Clinical use of such plasmids could potentially lead to their dissemination in the environment or in the patient. This could be of the utmost importance for the immunodepressed or for cystic fibrosis patients who suffer from chronic bronchopulmonary infections. 3 pCOR plasmids, for plasmid with conditional origin of replication, were specifically designed and developed for gene therapy. These new plasmids are small efficient transgene carriers and fulfill several quality assurance and safety
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Received 21 December 1998; accepted 12 April 1999 criteria. 4 These high copy number plasmids carry a minimal amount of bacterial sequences, a conditional origin of replication that prevents dissemination during production or therapy and do not contain an antibiotic resistance gene.
The pCOR backbone consists of three bacterial elements: the 0.4 kb R6K ␥ conditional origin of replication (ori ␥), which requires the R6K initiator protein to be functional, a 0.2 kb selectable tRNA suppressor gene (sup Phe), and a 0.4 kb cer (ColE1 resolution) fragment to resolve pCOR oligomers.
Such plasmids can only replicate in -producing bacteria considerably limiting their host range. pCOR selection uses expression of a synthetic amber suppressor tRNA gene, specific for phenylalanine (sup Phe), which does not require antibiotics. This suppressor corrects an amber mutation in argE gene making it possible for the recombinant host strain to grow on a minimal medium lacking arginine (Figure 1) .
The pCOR conditional origin of replication comes from a natural plasmid, R6K, rather than the widely used ColE1-derived plasmids. R6K is a 38 kb theta-replicating R (resistance) plasmid. R6K replication functions 5 are clustered in a 5.5 kb DNA fragment that contains three origins of replication: ␣ and ␤ that are mainly used, and ␥. All three are under the control of a single replication initiation protein, , the product of the pir gene. This protein binds to direct nucleotide sequence repeats (seven tandemly associated 22-bp direct repeats) at the origin of replication. It is a dual regulator, exerting both a positive effect on replication and negative feedback that maintains R6K at its characteristic copy number (15 per genome). Copy-up mutants inhibit replication less and maintain the ␥ origin at a high copy number. pir116 6 contains a single base mutation (CCC→CTC) that leads to a proline to leucine substitution at position 106 in . The minimum genetic information required to maintain R6K derivatives is the 400-bp ␥ origin (ori ␥) and the cis or trans-acting initiator protein. 5 Ori ␥ was isolated from the suicide vector pUT-T7pol 7 as a 0.4 kb BamHIEcoRI fragment and was ligated to the kanamycin resistance gene (Km R ) from pUC4K 8 to generate pXL2666. Ori ␥ replication and plasmid copy number were assayed in wild-type and copy-up backgrounds. pXL2666 was transferred into a pir (BW19094 9 ) and a pir116 strain ( BW19610 9 ) of E. coli. Agarose gel electrophoresis showed that there were five to 10 more plasmid DNA copies in the pir116 than in the pir strain, consistent with previous work 6 (data not shown). It also pointed out that the monomer/oligomer ratio of R6K-derivatives was affected by the presence of the copy-up mutation which resulted in the major plasmid species being multimers, mostly dimers ( Figure 2 ). Plasmid linearization by EcoRI indicated that these preparations contained a mixture of monomer and the corresponding oligomers. Topoisomerase treatment showed that the high molecular weight species were circular, supercoiled, plasmid multimers rather than catenanes. These plasmids are relaxed by DNA topoisomerase I and topoisomerase IV 10 and no decatenation by topoisomerase IV was observed, although this enzyme was active on kinetoplast DNA (data not shown). Plasmid multimerization is not compatible with pharmaceutical use due to low lot to lot reproducibility and too few molecules per unit weight. As well as reducing the number of independently segregating molecules, it may also severely reduce plasmid stability by affecting plasmid segregation during bacterial cell division. In our effort to resolve multimers, we tested the cer fragment that can promote monomerization independently of the replicon involved. This cis-acting DNA determinant reduces multimerization via a site-specific recombination event that requires only E. coli-encoded proteins. Two recombinases, XerC and XerD, are necessary, along with two accessory proteins, ArgR and PepA, that ensure exclusively intramolecular recombination at the cer site. 11 The 0.38 kb HpaII cer fragment 12 from the E. coli plasmid ColE1 was inserted into pXL2666. leading to the inactivation of cer, was introduced into pXL2666 to generate pXL2754 (ori ␥-Km R -⌬cer). This construct led to the production of plasmid multimers. These experiments were also carried out in XAC-1pir and XAC1pir116 strains (data not shown) which differ only by the pir allele. Thus, these results shed light on the link between plasmid multimerization/copy-up pir mutations and multimer resolution via cer-mediated intramolecular recombination.
An important original feature of pCOR is the absence of an antibiotic resistance gene for selection in E. coli. E. coli amber (TAG) suppressor tRNA genes do not contain any sequences derived from phages or transposons and are very small (less than 100 bp). They are efficient plasmid selection markers, even in high-density cultures of E. coli. 13 A synthetic amber suppressor tRNA gene, specific for phenylalanine (sup Phe) was used as the pCOR marker. sup Phe is expressed from a strong constitutive E. coli promoter, Plpp. This cassette (0.17 kb NarI-HindIII fragment) was isolated from pCT2-F 14 and was tested in E. coli XAC-1.
14 The chromosomal argE gene of XAC-1 contains an amber mutation that results in a truncated and therefore inactive product. As argE encodes N-acetylornithinase which is essential for arginine biosynthesis, this strain cannot grow in the absence of arginine. The suppressor tRNA sup Phe causes the correct translation of mRNA and the synthesis of an active full-length N-acetylornithinase. Thus, XAC-1 can grow on minimal medium lacking arginine as long as the plasmid is present, ensuring plasmid selection. However, this strain does not synthesize the R6K initiator protein and thus cannot replicate pCOR. Therefore, the -encoding gene, pir (or the copy-up mutant pir116), was inserted into the XAC-1 chromosome by homologous recombination. This method does not introduce any mobile genetic element, such as transposons or phages, that affect genome stability. Since there is no similarity between pir and the bacterial genome, pir or pir116 were inserted into the chromosomal uidA gene which encodes ␤-d-glucuronidase (EC 3.2.1.31), as described by Metcalf et al. 9 This gene 16 was successful in 18-34% of the deoxycholate-resistant and kanamycinsensitive segregants as demonstrated by the loss of ␤-glucuronidase activity. These clones were tested by assessing replication of an R6K derivative, pBW30. 9 The integrity of the bacterial genome in the region close to the site of homologous recombination was analyzed by PCR. Each unique amplified fragment, all of which were of the expected size, was identified by restriction analysis. The other genetic markers argE am , lacZ am , gyrA (nalidixic acid resistance), rpoB (rifampicin resistance), presence of episomal FЈ (susceptibility to M13 infection), were unaffected. The resulting pCOR host strains were named XAC1pir and XAC-1pir116. A pCOR plasmid (pXL2760: ori ␥-Km R -cer-sup Phe) was introduced into these strains and subsequent selection by plating on minimal medium demonstrated that these two strains allow pCOR replication and selection. The yield of pCOR from a smallscale culture of the XAC-1pir116 recombinant strain was similar to that of standard plasmids such as pUC and restriction analysis pattern was found to conform to theory (data not shown).
Since plasmid DNA degradation could occur during the production/purification process, a pCOR host lacking endonuclease I was constructed. Endonuclease I, encoded by endA, is a periplasmic DNase which is inhibited by RNA and internally cleaves native DNA into oligodeoxyribonucleotides in a sequence-independent fashion. 17 This enzyme is not essential and its biological role in E. coli is still unknown as mutants resemble wild-type cells in terms of growth rate, phage propagation and conjugation properties. 18 Various studies 19, 20 have found that EndA − strains produce DNA of higher quality than EndA + E. coli strains. A DNA fragment containing endA 21 was used to construct an M13 Km R suicide vector. The 0.37 kb FspI-PvuII central fragment was deleted removing 52% of endA. Gene replacement of the wild-type endA by the deleted endA was then obtained as previously described for the construction of XAC-1pir116. Genomic modification of the locus was verified by PCR and the absence of endonuclease I activity was demonstrated by two biochemical tests. First, gene replacement was monitored by a methyl green staining assay. 17 Second, the absence of endonuclease activity was assayed using the breakage of supercoiled DNA in the presence of coldshock fluid 22 a traD36 mutation on their episome, but no mutation affecting FЈ transfer ability has been described for XAC-1. traD is at the 5Ј end of one of the tra (transfer) operons and encodes a membrane protein that is directly involved in DNA transfer and DNA metabolism; 23 furthermore, traD mutants do not transfer DNA. 24 The presence of wild-type traD can be considered as a potential risk of plasmid dissemination between E. coli strains by nonspecific transfer of co-resident plasmids. 25 Therefore, the episomal traD gene of XAC-1pir116 was inactivated to abolish FЈ transfer. A 2 kb central fragment from traD, comprising 92% of the gene, was replaced with the 2 kb omega element from pHP45⍀ 26 by homologous recombination in XAC-1pir116 endA − . The omega element contains the aadA antibiotic resistance gene flanked by short inverted repeats. aadA encodes aminoglycoside-3 adenyltransferase and confers resistance to streptomycin and spectinomycin. The omega fragment was used because it prematurely terminates RNA and protein synthesis leading to the inactivation of the whole traD operon, not as a selectable marker (no antibiotic added during plasmid production). PCR and restriction analysis of the modified traD locus showed the expected pattern of amplified fragments demonstrating that gene replacement had occurred. The resultant strain was named TEX1. This new pCOR host strain, which is more suitable for industrial applications, is being evaluated.
Since gene therapy applications require large amounts of plasmid DNA, we assessed the pCOR host strain in fermentation experiments. Complex media containing yeast extract were used for fed-batch fermentation with XAC-1pir116. pCOR stability (more than 50 generations) makes it possible to use such non-selective media. In these conditions, XAC-1pir116 produced more than 40 g/l dry cell weight and 100 mg/l of pCOR pXL2774 (described in Figure 3 ) could be obtained from 2-liter fermentors (Table 1) . pCOR copy number was evaluated at 400-500 plasmids per cell and the rate of plasmid DNA synthesis was constant throughout fermentation. These results were extrapolated to an 800-liter fermentor suitable for manufacturing (Table 1) . To control culture conditions further, fermentation was also performed in the absence of yeast extract or any raw material from animal origin. Similar results (30 g/l dry cell weight and 100 mg/l of plasmid DNA) were obtained using a defined medium in 2-liter cultures with no loss of productivity (Table 1) .
pCOR gene transfer in vitro and in vivo was assessed and compared with commercial plasmids. Various pCOR plasmids were constructed with luc, the gene encoding firefly luciferase, or luc+, the engineered cytoplasmic luciferase gene. These plasmids were efficient in standard in vitro transfection of murine or human cell lines, giving higher levels of reporter gene activity than commercial plasmids (ie pGL3-basic; Promega, Madison, WI, USA) (data not shown). The same amount of luciferase expression cassette (3 × 10 12 ) in plasmids pGL3-control, pXL2774 and pXL3133 gave 0.07, 0.4 and 16.5 ng of luciferase per muscle (n = 24), respectively, when injected into the tibialis anterior of OF1 mice, as determined 72 h after injection (Figure 3 ). Thus the pCOR plasmid pXL3133 with an improved luciferase expression cassette is efficient at driving expression in muscle with levels of reporter gene activity at least 200-fold higher than that of a reference commercial vector. This result was comparable with those previously described with optimized ColE1-derived luciferase reporter plasmids. 27 Nonviral gene therapy has been based exclusively on E. coli plasmids derived from the ancestral ColE1 plasmid. These plasmids replicate in the absence of plasmidencoded proteins and their maintenance only requires E. coli host-encoded factors, such as DNA polymerases I and III and DNA-dependent RNA polymerase. To restrict plasmid host range to a single E. coli strain, we designed a plasmid derived from an E. coli natural narrow-host range plasmid, 28 R6K. Unlike ColE1 replication, R6K requires synthesis of the plasmid-coded protein that controls R6K replication through ori ␥ core sequences. pCOR replication is restricted to a specific bacterial host expressing . The ␥ origin from R6K has no identified open-reading frame, no undesirable sequences such as insertion sequences, and no element likely to direct its transfer to other bacteria. Although R6K contains two transfer origins, 29 they are not present in the ␥ origin of replication. Bacterial host FЈ episome transfer was abolished by insertional inactivation of the episomal traD to avoid low efficiency illegitimate co-transfer of pCOR.
The pCOR bacterial hosts, XAC-1pir116 or derivatives such as TEX1, are specifically engineered E. coli strains containing a chromosomal copy of a copy-up variant of pir, pir116, inserted into the nonessential uidA gene. R6K derivatives have a low copy number (around 15 copies per genome) which is not compatible with industrialscale production. Introduction of pir116 into the XAC-1 genome generates high copy number pCOR where plasmid multimerization was resolved by inserting the cer resolution site into pCOR. This is the first report of plasmid multimers in pir116 strains and of cer-mediated multimer resolution. We successfully cloned inserts of 8 kb into the pCOR backbone without any effect on plasmid copy number or stability indicating that pCOR or ColE1 derivatives appeared to have similar cloning capacity. R6K derivatives can accommodate inserts as large as 50-100 kb in a copy up context.
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R6K ␥ origin-bearing plasmids are widely used as suicide vectors in various bacteria, such as E. coli (non-pathogenic 9 or pathogenic 31 strains), Yersinia pestis, 32 Pasteurella, 33 Rhodobacter spheroides, 34 Pseudomonas putida or Klebsiella pneumoniae. 7 This strongly supports the fact that pCOR replication is totally dependent on initiator protein, and is thus biologically safe. The replication of natural R6K, which encodes , is restricted to E. coli and closely related bacteria. 28 To our knowledge, there is no report of a -like activity that may allow the replication of R6K derivatives. The potential risk of dissemination of pCOR would be restricted to a bacterium containing a resident R6K. However, incompatibility 35 between plasmids that share the major incompatibility factor 36 present in ori ␥ will lead to the loss of one of these plasmids and in any case, will result in only ephemeral pCOR replication since there is no selective advantage for bacteria to maintain a pCOR. pCOR replication is conditional and offers environmental advantages over current plasmids used in gene therapy.
Plasmids are maintained as stable extrachromosomal DNA molecules and are excellent vectors for the dissemination of antibiotic resistance genes 37 to a wide range of bacteria. Contamination of the final product intended for use in gene therapy with an antibiotic could cause allergic reactions. The use of a suppressor tRNA as a sel- ectable marker in bacteria is therefore an interesting alternative to the commonly used drug resistance markers. This tRNA, for which the anticodon was mutated to match the amber termination triplet, mediates plasmid selection in bacteria by suppression of an amber mutation in a gene essential for growth in the conditions used. This system developed by Normanly et al 14 proved to be efficient even in fermentation experiments. 13 An amber suppressor tRNA may cause readthrough at a significant number of natural termination codons and induce abnormal protein synthesis. However, this requires the conjunction of several events in mammals: (1) sufficient transcription of the suppressor tRNA in mammalian cells; (2) correct folding of this tRNA which is essential to its activity; (3) correct recognition; and (4) loading of a specific prokaryotic tRNA by a eukaryotic tRNA synthetase. Several experiments suggest that this is unlikely. Jacobson 38 obtained no aminoacylation of E. coli wild-type tRNA Phe with extracts from rat liver, mouse liver, maize or human spleen. It has also been shown that even if an E. coli suppressor tRNA Gln is expressed in mammalian cells, amber suppression is dependent upon coexpression of the E. coli GlnRS aminoacyl-tRNA synthetase gene. 39 Expression of sup Phe can only result from unknown cryptic eukaryotic expression signals in the plasmid backbone. To avoid spurious transcription, the eukaryotic expression cassette was inserted into pCOR such that the transgene and sup Phe gene are in opposite orientations.
Amber suppression is never complete and most known mammalian genes (79% 40 ) terminate in UAA or UGA.
Consistent with these observations, natural mammalian amber suppressor tRNA were isolated from calf liver. 41 We detected no apparent changes in cell viability when pCOR were transfected in murine or human cell lines in vitro or in murine muscle cells in vivo. Furthermore, when eukaryotic amber suppressor tRNA are expressed from appropriate eukaryotic expression signals, no adverse effects are noticed in transfected mammalian cells 42, 43 or in whole plants. 44 Thus, the bacterial suppressor tRNA Phe is unlikely to cause any deleterious effects in human cells and is an efficient selectable marker for pCOR in E. coli. Short (6 bp) immunostimulatory sequences (ISS) in bacterial plasmid DNA have been shown to trigger powerful immune responses and to affect gene expression in mice. 45 Schwartz et al 46 found that unmethylated CpG motifs caused inflammation of the lower respiratory tract of mice that received DNA by intratracheal instillation. Results obtained with oligonucleotides 47 gave indication of ISS potential to stimulate human B cells but the effects in man of plasmidic ISS have still to be investigated. However, the results obtained in mice suggest that these sequences may also cause problems in humans. The pCOR backbone does not contain ISS. Moreover, there are no 'two 5Ј purines -unmethylated CpG -two 3Ј pyrimidine' motifs in the pCOR backbone. In contrast, a plasmid containing the widely used Tn903 kanamycin resistance gene from pUC4K (Pharmacia Biotech, Uppsala, Sweden), for example VR1255, 27 and the ColE1-derived origin of replication from pBlueScript (Stratagene, La Jolla, CA, USA) contains nine such motifs. Thus pCOR should have less, if any, immunostimulatory Fermentation studies were carried out in 2-l fermentors (Setric, Toulouse, France) and culture conditions were scaled up to 800-l fermentors. The basal production medium contained salts (KH 2 PO 4 (8 g/l), K 2 HPO 4 (6.3 g/l), Na 2 HPO 4 (1.7 g/l) and trace elements), 10 mg/l thiamine and glucose as the carbon source; yeast extract (3 g/l) and NH 4 Cl (2.5 g/l) were used as the nitrogen source in complex and defined media, respectively. The complex medium was fed with 50% glucose, 0.7% MgSO 4 ,7H 2 O, 0.02% thiamine and 10% yeast extract, whereas for the defined medium feeding, the nitrogen was brought by the ammonia necessary to adjust the pH. The pH was automatically controlled and adjusted to a pH of 6.9-7.0 with 10% (w/v) ammonia. Aeration was kept at 75 l/h below 0.2 bars and dissolved oxygen was maintained at 40% air saturation by the impeller speed controller and, when necessary, by enrichment of the air stream with pure oxygen. All the process variables (pH, temperature, agitation, optical density, O 2 and CO 2 contents of exhaust gases) were monitored on-line. The feed media were added according to a pre-programmed time-based profile.
properties than standard ColE1-derived plasmids. If DNA vaccination is envisaged, immunostimulatory sequences could be added to the plasmid backbone. The pCOR backbone is significantly smaller (1 kb) than standard ColE1-derived plasmids (2.5 kb). It contains a minimal number of prokaryotic DNA sequences, the functions of which are known. The reduction of the amount of prokaryotic sequences in plasmid vectors is of importance since some of these sequences were shown in different studies to interfere with eukaryotic gene expression.
We aimed to improve biosafety during plasmid production and nonviral gene therapy by totally redesigning the plasmid backbone. The pCOR plasmid and host system are suitable for clinical and industrial applications in terms of safety (conditional origin of replication, no antibiotic marker, minimal plasmid sequences, inactivation of bacterial episome transfer) and gene expression (at least as efficient in vitro and in vivo as standard ColE1-derived plasmids, smaller size). In addition, pCOR has proved to be appropriate for production (high yield: 100-150 mg/l in fermentors, possibility of using defined media) and purification (small size, high copy number, elimination of endonuclease I activity of the host).
In conclusion, pCOR is an appropriate DNA vector for gene delivery which offers environmental advantages over current plasmids without any loss in gene transfer efficiency.
